In conclusion, neuroblastoma cells with high MYCN levels were more sensitive to both aryl sulfonamides (Fig. 9e) suggesting that this oncogenic subtype of tumours may respond well to these compounds in a clinical setting. This evidence concerns the gene MYCN and neuroblastoma.